Transcriptomics

Dataset Information

0

CART-19 Responses in Human CD19 Transgenic Mice [immunology platform]


ABSTRACT: The clinical success of chimeric antigen receptor (CAR) T-cell therapy for CD19+ B-cell malignancies may come at the expense of acute and chronic morbidities. Some patients suffer from significant, acute toxicities and those with persistent CAR T-cells require immunoglobulin therapy due to CAR-induced B-cell aplasia. Life-threatening effects include cytokine release syndrome, the exact etiology of which is unclear. To elucidate the underlying mechanisms of CAR-induced toxicities, we developed a mouse model in which human CD19 (hCD19)-specific mouse CAR T-cells were adoptively transferred into mice whose normal B-cells express a hCD19 transgene at hemizygous levels. In contrast to homozygous mice, hemizygous mice have higher B cell frequencies, providing a greater target antigen load to drive CAR-T cell activation. Hemizygous mice given a lethal dose of hCD19 transgene-expressing lymphoma cells and treated with CAR-T cells had undetectable levels of tumor. However, recipients experienced acute B-cell aplasia, morbidities and mortality in an antigen- and dose-dependent manner. IL-6, INF-g, and inflammatory pathway transcripts were enriched in affected tissues. As in patients, antibody-mediated neutralization of IL-6 blunted toxicity. This new model will prove useful in testing strategies designed to improve CD19-specific CAR T-cell therapy by reducing acute toxicities and reversing B-cell aplasia.

ORGANISM(S): Mus musculus domesticus

PROVIDER: GSE102617 | GEO | 2018/02/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2018-02-01 | GSE102618 | GEO
2017-10-24 | PXD007552 | Pride
2016-06-08 | GSE83076 | GEO
2022-10-31 | MTBLS5381 | MetaboLights
2020-12-11 | GSE153697 | GEO
2022-01-28 | PXD028109 | Pride
2022-07-27 | GSE191007 | GEO
2022-07-27 | GSE190843 | GEO
2022-07-27 | GSE190842 | GEO
2022-07-27 | GSE190841 | GEO